Literature DB >> 23764092

Vaccine strategies to enhance immune responses in the aged.

Julie S Lefebvre1, Laura Haynes.   

Abstract

The elderly population is more susceptible to infections with higher risks of morbidity and mortality. This is caused by the accumulation of immune defects with aging. The best way to protect people against infections is vaccination. Unfortunately, the same immune defects that render the elderly susceptible to infectious diseases also prevent the development of protective immunity following immunization. A good example of this is the influenza vaccine that only protects between 40 and 60% of the vaccinees over 65 years. In the past decade, tremendous efforts have been put toward improving the influenza vaccine for the elderly. We therefore use this example to present various strategies employed to overcome these age-associated immune defects and hence make vaccines more efficacious for the aged.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23764092      PMCID: PMC3775954          DOI: 10.1016/j.coi.2013.05.014

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  60 in total

Review 1.  Dysregulation of human Toll-like receptor function in aging.

Authors:  Albert C Shaw; Alexander Panda; Samit R Joshi; Feng Qian; Heather G Allore; Ruth R Montgomery
Journal:  Ageing Res Rev       Date:  2010-11-10       Impact factor: 10.895

2.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

3.  Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.

Authors:  Joan Puig-Barberà; Javier Diez-Domingo; Santiago Pérez Hoyos; Angel Belenguer Varea; David González Vidal
Journal:  Vaccine       Date:  2004-12-02       Impact factor: 3.641

4.  Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

Authors:  David Holland; Robert Booy; Ferdinandus De Looze; Peter Eizenberg; James McDonald; Jeff Karrasch; Maureen McKeirnan; Hatem Salem; Graham Mills; Jim Reid; Françoise Weber; Melanie Saville
Journal:  J Infect Dis       Date:  2008-09-01       Impact factor: 5.226

Review 5.  Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine.

Authors:  Paolo Durando; Rocco Iudici; Cristiano Alicino; Marisa Alberti; Daniela de Florentis; Filippo Ansaldi; Giancarlo Icardi
Journal:  Hum Vaccin       Date:  2011-01-01

6.  Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice.

Authors:  Jincun Zhao; Jingxian Zhao; Kevin Legge; Stanley Perlman
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

7.  Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy.

Authors:  A Iob; G Brianti; E Zamparo; T Gallo
Journal:  Epidemiol Infect       Date:  2005-08       Impact factor: 2.451

8.  Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels.

Authors:  Goutam Sen; Quanyi Chen; Clifford M Snapper
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

9.  Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

Authors:  Tamara K Berthoud; Matthew Hamill; Patrick J Lillie; Lenias Hwenda; Katharine A Collins; Katie J Ewer; Anita Milicic; Hazel C Poyntz; Teresa Lambe; Helen A Fletcher; Adrian V S Hill; Sarah C Gilbert
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 20.999

10.  Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.

Authors:  Salvatore Mannino; Marco Villa; Giovanni Apolone; Noel S Weiss; Nicola Groth; Ivana Aquino; Liana Boldori; Fausta Caramaschi; Antonio Gattinoni; Giancarlo Malchiodi; Kenneth J Rothman
Journal:  Am J Epidemiol       Date:  2012-08-31       Impact factor: 4.897

View more
  13 in total

1.  KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection.

Authors:  Lei Shi; Jia M Wang; Jun P Ren; Yong Q Cheng; Ruo S Ying; Xiao Y Wu; Shu M Lin; Jeddidiah W D Griffin; Guang Y Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Immunol       Date:  2013-12-13       Impact factor: 5.422

2.  HIV infection Worsens Age-Associated Defects in Antibody Responses to Influenza Vaccine.

Authors:  Varghese K George; Suresh Pallikkuth; Anita Parmigiani; Maria Alcaide; Margaret Fischl; Kristopher L Arheart; Savita Pahwa
Journal:  J Infect Dis       Date:  2015-01-02       Impact factor: 5.226

Review 3.  Innate immune responses in the ageing lung.

Authors:  D M Boe; L A Boule; E J Kovacs
Journal:  Clin Exp Immunol       Date:  2016-11-02       Impact factor: 4.330

4.  Loss of Phagocytic and Antigen Cross-Presenting Capacity in Aging Dendritic Cells Is Associated with Mitochondrial Dysfunction.

Authors:  Claire A Chougnet; Robert I Thacker; Hesham M Shehata; Cassandra M Hennies; Maria A Lehn; Celine S Lages; Edith M Janssen
Journal:  J Immunol       Date:  2015-08-05       Impact factor: 5.422

5.  Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Ann L Oberg; Michael T Zimmermann; Diane E Grill; Gregory A Poland
Journal:  Front Immunol       Date:  2016-11-02       Impact factor: 7.561

6.  Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.

Authors:  Susan L Baldwin; Fan-Chi Hsu; Neal Van Hoeven; Emily Gage; Brian Granger; Jeffrey A Guderian; Sasha E Larsen; Erica C Lorenzo; Laura Haynes; Steven G Reed; Rhea N Coler
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

Review 7.  Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.

Authors:  Sudeep Kumar; Raju Sunagar; Edmund Gosselin
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

8.  Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.

Authors:  Robert B Couch; José M Bayas; Covadonga Caso; Innocent Nnadi Mbawuike; Concepción Núñez López; Carine Claeys; Mohamed El Idrissi; Caroline Hervé; Béatrice Laupèze; Lidia Oostvogels; Philippe Moris
Journal:  BMC Infect Dis       Date:  2014-07-30       Impact factor: 3.090

Review 9.  Interventions to restore appropriate immune function in the elderly.

Authors:  Richard Aspinall; Pierre Olivier Lang
Journal:  Immun Ageing       Date:  2018-01-25       Impact factor: 6.400

10.  Attrition of T Cell Zone Fibroblastic Reticular Cell Number and Function in Aged Spleens.

Authors:  April R Masters; Evan R Jellison; Lynn Puddington; Kamal M Khanna; Laura Haynes
Journal:  Immunohorizons       Date:  2018-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.